New contrast agent enhances PET detection of neurodegeneration | Neurology
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
Communities Neuro New contrast agent enhances PET detection of neurodegeneration

New contrast agent enhances PET detection of neurodegeneration

Specialties - Neurology
FDDNP is a new compound that binds to beta-amyloid in senile plaques and to tau in neurofibrillary tangles. NEW YORK (Reuters Health) - FDDNP is a new compound that binds to beta-amyloid in senile plaques and to tau in neurofibrillary tangles.

When used as a tracer for positron-emission tomography (PET), FDDNP is better able to differentiate between Alzheimer's disease and other neurologic conditions, compared with conventional tracers, a research team reports in the December 21 issue of The New England Journal of Medicine.

Dr. Gary W. Small and colleagues, at the David Geffen School of Medicine at University of California, Los Angeles, enrolled 83 subjects with self-reported memory problems: 25 with Alzheimer's disease, 28 with mild cognitive impairment, and 30 healthy controls.

The participants underwent PET scanning with fluoro-D-glucose (FDG) and with FDDNP and 72 subjects underwent MRI scanning. The patients were also evaluated with multiple tests of cognition.

The results showed that FDDNP binding was the lowest in the control group, the highest in the Alzheimer's disease group, and intermediate in patients with mild cognitive impairment. This was seen for global values, as well as values in the medial and lateral temporal region, parietal region, posterior cingulate region and frontal region.

Using receiver operator characteristic curve analysis, FDDNP-PET global binding yielded the greatest diagnostic accuracy. Lower values for global FDDNP binding were correlated with higher scores in neurocognitive testing.

The FDDNP binding was also associated with neuropsychological test results that assessed several measures of cognitive domains.

Long-term follow-up for about 2 years indicated that clinically stable subjects had only minimal increases in global FDDNP binding. The three subjects whose disease had progressed had greater increases in FDDNP binding.

Dr. Small's team concludes that the "findings support the potential usefulness of FDDNP-PET in the development of surrogate markers for drug discovery aimed at blocking amyloid build-up and as a diagnostic tool."

N Engl J Med 2006;355:2652-2663.
 

Related Articles